Novel silica gel prosthesis material and application thereof

By adding hydrophobic silica nanoparticles, nanosilver, vitamin E and barium sulfate to the silica gel prosthesis, combined with vacuum stirring and crosslinking technology, the infection, rupture and oxidation of silica gel prosthesis during long-term implantation is solved. Problem, improving mechanical properties and biocompatibility, realizing multifunctional silicone prosthetic material.

CN119015495AInactive Publication Date: 2024-11-26GUANGDONG NANJU SILICONE MATERIAL TECH CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411104931.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing silicone prosthesis is prone to infection, rupture, cyst contracture, immune response and oxidative degradation after long-term implantation, and lacks the function of promoting tissue healing and inhibiting scar formation. X-ray opacity is insufficient, which increases the difficulty of postoperative monitoring. .

Method used

High molecular weight PDMS is used as the main material, combined with hydrophobic silica nanoparticles, nanosilver, vitamin E and barium sulfate and other functional additives, and uniform dispersion and cross-linking are achieved through vacuum stirring and defoaming technology, improving antibacterial, antioxidant and X-ray opacity, optimized curing treatment for enhanced mechanical properties and biocompatibility.

Benefits of technology

It significantly improves the anti-infection ability, mechanical strength, biocompatibility and long-term stability of silicone prosthesis, has anti-oxidation and healing functions, enhances X-ray opacity, reduces the risk of infection after implantation and difficulty in postoperative monitoring .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015495A_ABST
    Figure CN119015495A_ABST
Patent Text Reader

Abstract

According to the novel silica gel prosthesis material and the application thereof, a high-molecular-weight PDMS main body and a two-component system are adopted, so that excellent mechanical performance and biocompatibility are ensured, and controllable crosslinking is realized. Due to the low viscosity characteristic of the component A and a batch adding method, accurate dispersion of the functional additive is realized. The structural integrity is improved by vacuum stirring and defoaming, and uniform crosslinking is ensured by delayed addition of the component B. The multifunctional additives such as PDMS-PEG copolymer, nano-silver, vitamin E and barium sulfate endow the material with multiple functions. The cross-linked network is perfected through optimized curing and post-curing treatment, and the performance of the material is improved. The overall performance is enhanced through precise formula control and component synergistic effect. The process flexibility allows precise regulation of product performance at the molecular level. The silica gel prosthesis is excellent in mechanical strength, elasticity, biocompatibility, antibacterial property, long-term stability and the like, and a high-quality and multifunctional silica gel prosthesis material is provided for medical application.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention application relates to the field of medical aesthetics technology, and specifically to a new type of silicone prosthesis material and its application. Background Art

[0002] Since its introduction in the 1960s, silicone prostheses have been widely used in the fields of plastic surgery and reconstructive surgery, mainly due to their excellent biocompatibility, softness and durability. Traditional silicone prostheses are mainly made of polydimethylsiloxane (PDMS), which has the characteristics of high chemical stability, good biological inertness and excellent mechanical properties. Existing silicone prosthesis technology mainly revolves around material composition, surface treatment, shape design, internal structure and shell reinforcement. Typical silicone prostheses are composed of high molecular weight PDMS gel or elastomer as the shell, and the internal filler is usually low molecular weight PDMS oil or saline. In order to improve the biocompatibility of the prosthesis surface and reduce inflammatory response, researchers have used plasma treatment or special coating technology. At the same time, in order to meet different clinical needs and personalized requirements, prostheses of various shapes and sizes have been developed, and multi-chamber design has been introduced to improve morphological stability and naturalness. In addition, increasing the shell thickness or using special cross-linking technology to improve the anti-rupture performance of the prosthesis is also an important direction of existing technology.

[0003] However, despite the significant progress made in existing technologies, silicone prostheses still have some urgent problems to be solved. First, the risk of infection after long-term implantation in the body is always an important challenge, especially after the formation of biofilm on the surface of the prosthesis, which is more likely to breed bacteria. Second, although the durability of modern prostheses has been greatly improved, they may still rupture after long-term use, resulting in leakage of fillings. Capsular contracture is another common problem. The fibrous capsule formed in the body may shrink, causing the prosthesis to become hard and deformed, affecting the aesthetic effect and possibly causing pain. After long-term implantation in the body, silicone materials may also age, resulting in decreased mechanical properties and morphological changes. Although silicone has good biocompatibility, it may still cause immune or allergic reactions in some patients. In addition, traditional silicone prostheses mainly focus on morphological reconstruction and lack additional functionality, such as promoting tissue healing or inhibiting scar formation. In terms of medical imaging examinations, the X-ray opacity of conventional silicone prostheses is insufficient, which increases the difficulty of postoperative monitoring. Finally, after long-term exposure to the in vivo environment, the insufficient antioxidant properties of silicone materials may lead to oxidative degradation, affecting the long-term stability of the prosthesis. Summary of the invention

[0004] In order to solve or partially solve the problems existing in the related technologies, the present invention provides a new silicone prosthesis material and its application. The material of the present invention further improves the anti-infection ability, mechanical strength, biocompatibility and long-term stability on the basis of maintaining the original advantages of silicone, and at the same time gives the material new functions, such as anti-oxidation, promoting healing, etc., to meet the growing clinical needs and patient expectations.

[0005] The first aspect of the present invention provides a method for preparing a novel silicone prosthesis material, comprising the following steps:

[0006] (1) Add 80-95 parts by weight of medical grade PDMS A component into a vacuum mixer;

[0007] (2) adding 1-8 parts by weight of hydrophobic silica nanoparticles in batches, stirring after each addition until all the particles are added;

[0008] (3) stirring and degassing the mixture under vacuum conditions;

[0009] (4) Add the following functional components in sequence and stir:

[0010] a) 0.5-3 parts by weight of a medical grade PDMS-PEG copolymer;

[0011] b) 0.05-0.5 parts by weight of nano silver particles;

[0012] c) 0.1-1 parts by weight of vitamin E;

[0013] d) 0.5-3 parts by weight of barium sulfate;

[0014] (5) stirring and degassing the mixture under vacuum conditions;

[0015] (6) Add 5-15 parts by weight of medical-grade PDMS B component containing 5-10% hydrogen silicone oil and stir quickly and evenly;

[0016] (7) stirring and degassing the final mixture for a short time under vacuum conditions;

[0017] (8) injecting the mixture into a pre-prepared mold;

[0018] (9) placing the mold after injection molding in an environment of 65-75° C. for curing for 6-8 hours;

[0019] (10) The cured product is removed from the mold and post-cured in an environment of 55-65° C. for 4-6 hours;

[0020] (11) Surface treatment, cleaning and sterilization of products.

[0021] Furthermore, 88 parts by weight of medical grade PDMS A component was added in step (1).

[0022] Furthermore, 5 parts by weight of hydrophobic silica nanoparticles are added in step (2).

[0023] Furthermore, 1.5 parts by weight of medical grade PDMS-PEG copolymer is added in step (4)a.

[0024] Furthermore, 0.2 parts by weight of nano silver particles are added in step (4)b.

[0025] Furthermore, 0.5 parts by weight of vitamin E is added in step (4) c.

[0026] Furthermore, 1.5 parts by weight of barium sulfate is added in step (4)d.

[0027] Furthermore, in step (6), 10 parts by weight of a medical-grade PDMS B component containing 10% hydrogen-containing silicone oil is added.

[0028] The second aspect of the present application provides a novel silicone prosthesis material, which is prepared according to the above-mentioned preparation method.

[0029] The third aspect of the present application provides an application of a new silicone prosthesis material for making a silicone prosthesis.

[0030] It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the present invention.

[0031] Beneficial technical effects of the present invention:

[0032] The novel medical grade silicone prosthesis material and the preparation method thereof of the present invention have advantages in many aspects. The use of high molecular weight PDMS as the main material ensures good mechanical properties and biocompatibility, while the two-component system allows stability to be maintained before use and a controllable cross-linking process to be achieved after mixing. By utilizing the low viscosity characteristics of component A and the method of multiple batch additions, the functional additives are accurately dispersed and the agglomeration of nanoparticles is effectively prevented. The vacuum stirring and degassing technology effectively removes the bubbles in the system and improves the structural integrity of the product. The delayed addition of component B ensures that the cross-linking reaction is carried out in a uniformly dispersed system, and the degree of cross-linking can be accurately controlled by adjusting the content of hydrogen-containing silicone oil and the reaction temperature. The introduction of multifunctional additives, such as PDMS-PEG copolymer to improve surface properties, nanosilver to provide antibacterial properties, vitamin E to enhance antioxidant capacity, and barium sulfate to enhance X-ray opacity, makes the material have multiple functions. The optimized curing and post-curing treatments improve the cross-linking network, reduce residual stress, and improve the thermal stability and mechanical properties of the material. The precise formula control and the synergistic effect between the components further enhance the overall performance of the material. The flexibility of this process allows precise control of the material structure at the molecular level by adjusting various parameters, thereby achieving precise regulation of the performance of the final product. In summary, the present invention exhibits excellent comprehensive properties in terms of mechanical strength, elasticity, biocompatibility, antibacterial properties and long-term stability, providing a high-quality, multifunctional silicone prosthesis material option for medical applications. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 This is an electron microscope image of the surface of the silicone prosthesis product obtained in Example 2 of the present invention. DETAILED DESCRIPTION

[0034] The optional embodiments of the present invention will be described in more detail below with reference to the accompanying drawings. Although the optional embodiments of the present invention are shown in the accompanying drawings, it should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments described herein. On the contrary, these embodiments are provided to make the present invention more thorough and complete, and to fully convey the scope of the present invention to those skilled in the art.

[0035] The terms used in this application are only for the purpose of describing specific embodiments and are not intended to limit this application. The singular forms of "a", "said" and "the" used in this application and the appended claims are also intended to include plural forms unless the context clearly indicates other meanings. It should also be understood that the term "and / or" used herein refers to and includes any or all possible combinations of one or more associated listed items.

[0036] The present invention is described in detail below, specifically as follows:

[0037] The present invention provides a method for preparing a novel silicone prosthesis material, comprising the following steps:

[0038] (1) Add 80-95 parts by weight of medical grade PDMS A component into a vacuum mixer;

[0039] (2) adding 1-8 parts by weight of hydrophobic silica nanoparticles in batches, stirring after each addition until all the particles are added;

[0040] (3) stirring and degassing the mixture under vacuum conditions;

[0041] (4) Add the following functional components in sequence and stir:

[0042] a) 0.5-3 parts by weight of a medical grade PDMS-PEG copolymer;

[0043] b) 0.05-0.5 parts by weight of nano silver particles;

[0044] c) 0.1-1 parts by weight of vitamin E;

[0045] d) 0.5-3 parts by weight of barium sulfate;

[0046] (5) stirring and degassing the mixture under vacuum conditions;

[0047] (6) Add 5-15 parts by weight of medical-grade PDMS B component containing 5-10% hydrogen silicone oil and stir quickly and evenly;

[0048] (7) stirring and degassing the final mixture for a short time under vacuum conditions;

[0049] (8) injecting the mixture into a pre-prepared mold;

[0050] (9) placing the mold after injection molding in an environment of 65-75° C. for curing for 6-8 hours;

[0051] (10) The cured product is removed from the mold and post-cured in an environment of 55-65° C. for 4-6 hours;

[0052] (11) Surface treatment, cleaning and sterilization of products.

[0053] The use of high molecular weight PDMS terminated with vinyl as component A provides sufficient reaction sites for subsequent cross-linking reactions. This high molecular weight PDMS has good mechanical properties and biocompatibility, and is the basis for forming a stable network structure. The PDMS mixture containing hydrogen silicone oil in component B is used as a cross-linking agent, and its Si-H group can undergo addition reaction with the vinyl group of component A. This two-component system allows the stability of each component to be maintained before use, while enabling a controllable cross-linking process after mixing.

[0054] In the initial stage, only component A is added, and its lower viscosity (usually in the range of 3000-5000mPa·s) is used to create favorable conditions for the dispersion of functional additives. This step is crucial to ensure the uniform distribution of nanoscale additives (such as hydrophobic silica nanoparticles and nanosilver particles) throughout the system. The process of multiple batch additions and repeated stirring overcomes the van der Waals and electrostatic forces between nanoparticles through shear force and intermolecular interactions, prevents agglomeration, and achieves uniform dispersion.

[0055] Stirring and degassing are performed under vacuum conditions, and the principle of pressure difference is used to remove bubbles in the system. When the external pressure decreases, the volume of the bubbles increases, the buoyancy increases, and it is easier for them to rise to the surface and burst. This process reduces the generation and retention of bubbles, which helps to improve the structural integrity of the final product.

[0056] The addition of component B is postponed until all functional additives are fully dispersed to ensure that the crosslinking reaction starts in a uniformly dispersed system. The crosslinking process is mainly carried out through the hydrosilation reaction, that is, the addition reaction between the Si-H group and the Si-CH=CH2 group. This reaction is carried out under the action of organic peroxides, forming Si-CH2-CH2-Si bonds and constructing a three-dimensional network structure. The reaction speed and degree can be controlled by adjusting the content of hydrogenated silicone oil in component B and the reaction temperature.

[0057] Functional additives mechanism of action:

[0058] PDMS-PEG copolymer: Improves surface properties and increases biocompatibility by forming a hydrophilic layer on the silica surface.

[0059] Nanosilver: Utilizes the release and nanoscale effect of silver ions to provide antibacterial properties.

[0060] Vitamin E: As an antioxidant, it prevents materials from oxidative aging by capturing free radicals.

[0061] Barium sulfate: Due to its high atomic number, it effectively absorbs X-rays, increasing the X-ray opacity of the material.

[0062] During the curing process, the increase in temperature accelerates the cross-linking reaction rate and promotes the formation of the network structure. Post-curing treatment further improves the cross-linking network, reduces residual stress, and improves the thermal stability and mechanical properties of the material. This process involves the rearrangement of polymer chain segments and further reaction of residual reactive groups.

[0063] The core of this process is the precise control of the material system from the molecular level to the macroscopic scale. By adjusting the proportion of each component, reaction conditions and processing parameters, the network structure of the material can be designed and regulated at the molecular level, thereby achieving precise control of the mechanical properties, surface characteristics and functionality of the final product.

[0064] In one embodiment of the present invention, 88 parts by weight of medical grade PDMS A component is added in step (1).

[0065] In one embodiment of the present invention, 5 parts by weight of hydrophobic silica nanoparticles are added in step (2).

[0066] In one embodiment of the present invention, 1.5 parts by weight of medical grade PDMS-PEG copolymer is added in step (4)a.

[0067] In one embodiment of the present invention, 0.2 parts by weight of nano-silver particles are added in step (4)b.

[0068] In one embodiment of the present invention, 0.5 parts by weight of vitamin E is added in step (4) c.

[0069] In one embodiment of the present invention, 1.5 parts by weight of barium sulfate is added in step (4)d.

[0070] In one embodiment of the present invention, 10 parts by weight of medical grade PDMS B component containing 10% hydrogen silicone oil is added in step (6).

[0071] The second aspect of the present application provides a novel silicone prosthesis material, which is prepared according to the above-mentioned preparation method.

[0072] The third aspect of the present application provides an application of a new silicone prosthesis material for making a silicone prosthesis.

[0073] The excellent performance of this new medical-grade silicone prosthetic material stems from its carefully designed multi-component system and precisely controlled preparation process. First, the optimized ratio of medical-grade PDMS component A and component B (80-95 parts by weight of component A to 5-15 parts by weight of component B) ensures that the final product has an ideal cross-linking density. This optimized cross-linking structure achieves a balance between mechanical properties and biocompatibility at the molecular level, providing excellent mechanical strength and elasticity while maintaining the necessary flexibility of the material.

[0074] The addition of hydrophobic silica nanoparticles (1-8 parts by weight) plays a key reinforcing role. These nanoparticles significantly improve the mechanical strength and durability of the material through physical entanglement and possible chemical bonding with the PDMS molecular chains. At the same time, the uniform dispersion of the nanoparticles increases the cohesion of the material and improves its tear resistance. This nanocomposite structure also forms microscopic roughness on the surface of the material, which helps to reduce bacterial attachment.

[0075] The introduction of medical-grade PDMS-PEG copolymer (0.5-3 parts by weight) is the key to improving biocompatibility. The PEG segments form a hydrophilic layer on the surface of the material, which effectively reduces protein adsorption and cell adhesion, thereby enhancing the biocompatibility of the material. This surface modification not only improves the compatibility of the material with human tissue, but also helps reduce the initial adhesion of bacteria.

[0076] The addition of nanosilver particles (0.05-0.5 parts by weight) gives the material lasting antibacterial properties. By pre-dispersing the nanosilver in a small amount of PDMS A component, its uniform distribution throughout the material is ensured. This dispersion allows the nanosilver to slowly and continuously release silver ions, providing a long-term antibacterial effect. The semi-transparent nature of the PDMS network structure itself allows water and oxygen to penetrate slowly, controlling the generation and release rate of silver ions, further ensuring the persistence of antibacterial properties.

[0077] Vitamin E (0.1-1 parts by weight) is a powerful antioxidant that plays a key protective role in the material. It can effectively capture free radicals, block oxidation chain reactions, and significantly improve the stability of the material under long-term use and accelerated aging conditions. This not only extends the service life of the material, but also reduces degradation products, further improving biosafety.

[0078] The addition of barium sulfate (0.5-3 parts by weight) is mainly to improve the X-ray opacity of the material, which is convenient for medical imaging examination. However, at the same time, the presence of barium sulfate particles also has a subtle effect on the mechanical properties of the material, playing a certain role in strengthening.

[0079] Multiple vacuum stirring and degassing steps throughout the preparation process ensure uniform distribution of components and thorough removal of bubbles, which is critical to the consistency and reliability of the final performance of the material. Temperature and time control during the curing and post-curing process (65-75°C curing for 6-8 hours, 55-65°C post-curing for 4-6 hours) ensures full cross-linking reaction and optimizes the final performance of the material.

[0080] This multi-component, multifunctional design, combined with a precisely controlled preparation process, enables the new medical-grade silicone prosthesis material to exhibit excellent comprehensive performance in terms of mechanical properties, biocompatibility, antibacterial properties, and long-term stability. The synergistic effects between the various components in the material, such as the interaction between nanosilver and the PDMS network and the protective effect of vitamin E on the overall system, further enhance the overall performance and functional durability of the material.

[0081] For the purpose of greater clarity, the invention is described in detail through the following examples.

[0082] Example 1

[0083] Embodiment 1:

[0084] The new silicone prosthesis material was prepared according to the following steps:

[0085] (1) Add 80 parts by weight of medical grade PDMS A component into a vacuum mixer;

[0086] (2) adding 1 part by weight of hydrophobic silica nanoparticles in batches, stirring after each addition until all the particles are added;

[0087] (3) stirring and degassing the mixture under vacuum conditions;

[0088] (4) Add the following functional components in sequence and stir:

[0089] a) 0.5 parts by weight of medical grade PDMS-PEG copolymer;

[0090] b) 0.05 parts by weight of nano silver particles;

[0091] c) 0.1 parts by weight of vitamin E;

[0092] d) 0.5 parts by weight of barium sulfate;

[0093] (5) stirring and degassing the mixture under vacuum conditions;

[0094] (6) Add 5 parts by weight of medical-grade PDMS B component containing 5% hydrogenated silicone oil and stir quickly to mix well;

[0095] (7) stirring and degassing the final mixture for a short time under vacuum conditions;

[0096] (8) injecting the mixture into a pre-prepared mold;

[0097] (9) The mold after injection molding was placed in an environment of 65° C. for curing for 6 hours;

[0098] (10) The cured product is removed from the mold and post-cured in an environment of 55° C. for 4 hours;

[0099] (11) Surface treatment, cleaning and sterilization of products.

[0100] Embodiment 2:

[0101] The new silicone prosthesis material was prepared according to the following steps:

[0102] (1) Add 88 parts by weight of medical grade PDMS A component into a vacuum mixer;

[0103] (2) adding 5 parts by weight of hydrophobic silica nanoparticles in batches, stirring after each addition until all the particles are added;

[0104] (3) stirring and degassing the mixture under vacuum conditions;

[0105] (4) Add the following functional components in sequence and stir:

[0106] a) 1.5 parts by weight of medical grade PDMS-PEG copolymer;

[0107] b) 0.2 parts by weight of nano silver particles;

[0108] c) 0.5 parts by weight of vitamin E;

[0109] d) 1.5 parts by weight of barium sulfate;

[0110] (5) stirring and degassing the mixture under vacuum conditions;

[0111] (6) Add 10 parts by weight of medical-grade PDMS B component containing 10% hydrogenated silicone oil and stir quickly;

[0112] (7) stirring and degassing the final mixture for a short time under vacuum conditions;

[0113] (8) injecting the mixture into a pre-prepared mold;

[0114] (9) The mold after injection molding was placed in an environment of 70° C. for curing for 7 hours;

[0115] (10) The cured product is taken out of the mold and post-cured in an environment of 60° C. for 5 hours;

[0116] (11) Surface treatment, cleaning and sterilization of products.

[0117] Embodiment 3:

[0118] The new silicone prosthesis material was prepared according to the following steps:

[0119] (1) Add 95 parts by weight of medical grade PDMS A component into a vacuum mixer;

[0120] (2) adding 8 parts by weight of hydrophobic silica nanoparticles in batches, stirring after each addition until all the particles are added;

[0121] (3) stirring and degassing the mixture under vacuum conditions;

[0122] (4) Add the following functional components in sequence and stir:

[0123] a) 3 parts by weight of medical grade PDMS-PEG copolymer;

[0124] b) 0.5 parts by weight of nano silver particles;

[0125] c) 1 part by weight of vitamin E;

[0126] d) 3 parts by weight of barium sulfate;

[0127] (5) stirring and degassing the mixture under vacuum conditions;

[0128] (6) Add 15 parts by weight of medical-grade PDMS B component containing 10% hydrogenated silicone oil and stir quickly to mix well;

[0129] (7) stirring and degassing the final mixture for a short time under vacuum conditions;

[0130] (8) injecting the mixture into a pre-prepared mold;

[0131] (9) The mold after injection molding was placed in an environment of 75° C. for curing for 8 hours;

[0132] (10) The cured product is removed from the mold and post-cured in an environment of 65° C. for 6 hours;

[0133] (11) Surface treatment, cleaning and sterilization of products.

[0134] Test Example 1

[0135] 1. Experimental purpose:

[0136] To verify the mechanical property stability and biocompatibility of the new medical-grade silicone prosthesis material in a long-term simulated physiological environment, and compare it with commercially available medical silicone prosthesis materials.

[0137] 2. Material preparation:

[0138] a) Test sample: New medical grade silicone prosthesis material prepared according to the formula

[0139] b) Control sample: Commercially available medical silicone prosthesis material

[0140] c) Simulated body fluid (SBF): prepared according to the Kokubo method

[0141] 3. Sample preparation:

[0142] a) Dumbbell-shaped specimen: According to ASTM D412 standard, Type C size

[0143] Length: 115mm

[0144] Narrow section width: 6mm

[0145] Thickness: 2mm b) Disc sample: for surface and biological testing

[0146] Diameter: 14mm

[0147] Thickness: 1 mm For each material, 60 dumbbell-shaped samples and 60 disc samples were prepared.

[0148] 4. Experimental setup:

[0149] a) Soaking conditions: 37±0.5℃ SBF

[0150] b) Total experimental period: 90 days

[0151] c) Test time points: 0 days (initial), 30 days, 60 days, 90 days

[0152] 5. Test items and methods:

[0153] 5.1 Mechanical properties test:

[0154] Equipment: Universal material testing machine (Instron 5567)

[0155] Method: Tensile test according to ASTM D412

[0156] Test parameters:

[0157] Tensile rate: 500mm / min

[0158] Preload: 0.5N

[0159] 10 samples were tested at each time point

[0160] Measuring indicators:

[0161] Tensile strength(MPa)

[0162] Elongation at break (%)

[0163] 100% modulus (MPa)

[0164] 5.2 Surface characteristics test:

[0165] Equipment: Contact angle meter (DataPhysics OCA 15EC)

[0166] Method: Water contact angle measurement by sessile drop method

[0167] Test parameters:

[0168] Droplet volume: 5 μL

[0169] Tested at room temperature (25°C)

[0170] Each sample was measured at 5 different locations

[0171] Measurement index: Water contact angle (°)

[0172] 5.3 Protein adsorption test:

[0173] Materials: FITC-labeled bovine serum albumin (BSA-FITC)

[0174] Method: a) Immerse the sample in a 50 μg / mL BSA-FITC solution and incubate at 37°C for 2 hours b) Wash thoroughly with PBS to remove unadsorbed proteins c) Place the sample in a 1% SDS solution for ultrasonic treatment and collect the eluate

[0175] Measurement: Measure the fluorescence intensity of the eluate using a fluorescence spectrophotometer

[0176] Standard curve: Established using BSA-FITC solution with known concentrations

[0177] Measurement index: Protein adsorption per unit area (μg / cm 2 )

[0178] 5.4 Cytocompatibility test:

[0179] Cells: Human dermal fibroblasts (HDF)

[0180] Methods: a) Cell Adhesion:

[0181] 1×10 5 cells / mL cell suspension

[0182] After 4 hours of culture, the number of adherent cells was determined using the CCK-8 kit. b) Cell proliferation:

[0183] 5×10 4 cells / mL cell suspension

[0184] After 1, 3, and 5 days of culture, cell proliferation was measured using the CCK-8 kit.

[0185] Measuring indicators:

[0186] Cell adhesion rate (%)

[0187] Cell proliferation rate (relative to day 1)

[0188] Table 1: Mechanical properties test results (mean ± standard deviation, n = 10)

[0189]

[0190] Table 2: Surface properties and biocompatibility test results (mean ± SD, n = 5)

[0191]

[0192]

[0193] In summary, this comprehensive evaluation experiment proves that the new medical-grade silicone prosthesis material is superior to the commercially available control product in terms of long-term mechanical property stability, surface properties and biocompatibility. Its excellent performance and stability make it very suitable for long-term implanted medical devices, especially in applications that require maintenance of long-term mechanical properties and good tissue compatibility. These results provide strong experimental support for the potential advantages of this material in clinical applications.

[0194] Test Example 2

[0195] 1. Experimental purpose:

[0196] To evaluate the durability of the antimicrobial properties of a novel medical-grade silicone prosthetic material under long-term immersion conditions.

[0197] 2. Material preparation:

[0198] a) Test sample: New medical grade silicone prosthesis material containing nanosilver

[0199] b) Control sample: Medical silicone material without antibacterial ingredients

[0200] c) Phosphate buffered saline (PBS, pH 7.4)

[0201] d) Bacterial strains: Staphylococcus aureus (ATCC 25923) and Escherichia coli (ATCC 25922)

[0202] e) Nutrient agar and nutrient broth

[0203] 3. Sample preparation:

[0204] Prepare disc samples with a diameter of 15 mm and a thickness of 2 mm. Prepare 120 samples for each material.

[0205] 4. Experimental steps:

[0206] 4.1 Sample immersion:

[0207] The samples were placed in sterile PBS and immersed at 37°C.

[0208] Immersion time points: 0 day, 30 days, 90 days, 180 days.

[0209] Thirty samples were taken out for testing at each time point.

[0210] 4.2 Inhibition zone test (at each time point):

[0211] a) Spread about 10% of the medium evenly on a nutrient agar plate. 6 CFU / mL of bacterial suspension.

[0212] b) Gently place the sample on the inoculated agar surface.

[0213] c) Incubate at 37°C for 24 hours.

[0214] d) Measure and record the diameter of the inhibition zone.

[0215] e) Five samples were tested for each bacteria.

[0216] 4.3 Colony counting method (at each time point):

[0217] a) Place the sample into nutrient broth containing approximately 105 CFU / mL of bacterial suspension.

[0218] b) Incubate at 37°C for 24 hours.

[0219] c) Take the culture solution for serial dilution and then spread it on nutrient agar plates.

[0220] d) After incubation at 37°C for 24 hours, the colonies were counted.

[0221] e) Five samples were tested for each bacteria.

[0222] 5. Data recording and analysis:

[0223] The diameter of the inhibition zone was recorded for each sample.

[0224] Calculate the antibacterial rate of the colony counting method: Antibacterial rate (%) = (control group CFU-test group CFU) / control group CFU × 100%

[0225] Statistical analysis was performed using GraphPad Prism software using two-way ANOVA and Tukey's multiple comparison test.

[0226] 6. Experimental results:

[0227] Table 1: Diameter of inhibition zone (mm, mean ± SD, n = 5)

[0228]

[0229]

[0230] Table 2: Antibacterial rate (%, mean ± SD, n = 5)

[0231]

[0232] In summary, this long-term antibacterial performance evaluation experiment strongly proves that the new medical-grade silicone prosthesis material has long-lasting, stable and efficient antibacterial properties. Its ability to maintain significant antibacterial activity after 180 days of long-term immersion provides strong support for the application of this material in medical devices that require long-term anti-infection protection. This long-lasting antibacterial performance is expected to significantly reduce the risk of implant-related infection and improve patient safety and treatment outcomes.

[0233] Test Example 3

[0234] The embodiments of the present invention have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and changes will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The selection of terms used herein is intended to best explain the principles of the embodiments, practical applications, or improvements to the technology in the market, or to enable other persons of ordinary skill in the art to understand the embodiments disclosed herein.

Claims

1. A method for preparing a novel silicone prosthesis material, characterized in that: The following steps are involved: (1) Add 80-95 parts by weight of medical grade PDMS A component into a vacuum mixer; (2) adding 1-8 parts by weight of hydrophobic silica nanoparticles in batches, stirring after each addition until all the particles are added; (3) stirring and degassing the mixture under vacuum conditions; (4) Add the following functional components in sequence and stir: a) 0.5-3 parts by weight of a medical grade PDMS-PEG copolymer; b) 0.05-0.5 parts by weight of nano silver particles; c) 0.1-1 parts by weight of vitamin E; d) 0.5-3 parts by weight of barium sulfate; (5) stirring and degassing the mixture under vacuum conditions; (6) Add 5-15 parts by weight of medical-grade PDMS B component containing 5-10% hydrogen silicone oil and stir quickly and evenly; (7) stirring and degassing the final mixture for a short time under vacuum conditions; (8) injecting the mixture into a pre-prepared mold; (9) placing the mold after injection molding in an environment of 65-75° C. for curing for 6-8 hours; (10) The cured product is removed from the mold and post-cured in an environment of 55-65° C. for 4-6 hours; (11) Surface treatment, cleaning and sterilization of products.

2. The method according to claim 1, characterized in that In step (1), 88 parts by weight of a medical grade PDMSA component was added.

3. The method according to claim 1, characterized in that In step (2), 5 parts by weight of hydrophobic silica nanoparticles were added.

4. The method according to claim 1, characterized in that: In step (4) a, 1.5 parts by weight of medical grade PDMS-PEG copolymer was added.

5. The method according to claim 1, characterized in that In step (4) b, 0.2 parts by weight of nano silver particles are added.

6. The method according to claim 1, characterized in that In step (4) c, add 0.5 parts by weight of vitamin E.

7. The method according to claim 1, characterized in that In step (4) d, 1.5 parts by weight of barium sulfate was added.

8. The method according to claim 1, characterized in that In step (6), 10 parts by weight of medical grade PDMS B component containing 10% hydrogen silicone oil was added.

9. A new type of silicone prosthesis material, characterized in that: Prepared according to the preparation method according to any one of claims 1 to 7.

10. Application of a new type of silicone prosthesis material, characterized in that: Used in making silicone prostheses.

Citation Information

Patent Citations

  • Silicon dioxide etching solution for high-selectivity semiconductor chip, preparation method and application of silicon dioxide etching solution

    CN116855251A

  • Preparation method of room-temperature vulcanized silicone rubber for fixing artificial limbs

    CN118325343A

  • Medical silicon rubber having high mechanical property and preparation method thereof

    US20210395527A1